相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
A. Pardanani et al.
LEUKEMIA (2011)
DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia
M. Ewalt et al.
BLOOD CANCER JOURNAL (2011)
Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia
Cynthia L. Fisher et al.
BLOOD (2010)
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
Franz X. Schaub et al.
BLOOD (2010)
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Stephen T. Oh et al.
BLOOD (2010)
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission
Olivier Nibourel et al.
BLOOD (2010)
Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia
Ciro R. Rinaldi et al.
BLOOD (2010)
Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations
Wen-Chien Chou et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis
Johanna Flach et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1
Sang-Wang Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Lnk constrains myeloproliferative diseases in mice
Alexey Bersenev et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1
Alexander Kohlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A. Tefferi et al.
LEUKEMIA (2010)
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
A. Pardanani et al.
LEUKEMIA (2010)
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A. Tefferi
LEUKEMIA (2010)
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
R. Jaeger et al.
LEUKEMIA (2010)
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
O. Kosmider et al.
LEUKEMIA (2010)
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Myunggon Ko et al.
NATURE (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (vol 462, pg 739, 2010)
Lenny Dang et al.
NATURE (2010)
Deregulation of H3K27 methylation in cancer
Eva Martinez-Garcia et al.
NATURE GENETICS (2010)
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
Gorica Nikoloski et al.
NATURE GENETICS (2010)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst et al.
NATURE GENETICS (2010)
LNK Mutations in JAK2 Mutation-Negative Erythrocytosis.
Terra L. Lasho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
DNMT3A Mutations in Acute Myeloid Leukemia.
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Array-based genomic resequencing of human leukemia
Y. Yamashita et al.
ONCOGENE (2010)
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
Francis H. Grand et al.
BLOOD (2009)
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
Veronique Gelsi-Boyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function
Daniel Trageser et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
Sigal Gery et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
A. Tefferi et al.
LEUKEMIA (2009)
Mutations of ASXL1 gene in myeloproliferative neoplasms
N. Carbuccia et al.
LEUKEMIA (2009)
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Mark A. Dawson et al.
NATURE (2009)
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Masashi Sanada et al.
NATURE (2009)
Acquired mutations in TET2 are common in myelodysplastic syndromes
Saskia M. C. Langemeijer et al.
NATURE GENETICS (2009)
OPINION Rethinking how DNA methylation patterns are maintained
Peter A. Jones et al.
NATURE REVIEWS GENETICS (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Mamta Tahiliani et al.
SCIENCE (2009)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
A. Pardanani et al.
LEUKEMIA (2007)
Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor
Yang-Sook Cho et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
Induction of tumors in mice by genomic hypomethylation
F Gaudet et al.
SCIENCE (2003)
分享论文
